Pluripotent stem cell that can be isolated from body tissue

Abstract

Objects of the present invention are to provide a method for directly obtaining pluripotent stern cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stern cells that can be isolated from body tissue.

1 - 3 . (canceled) 
     
     
         4 . A cell fraction comprising at least 30% isolated SSEA-3(+) pluripotent cells (SSEA-3 (+) Muse cells) characterized by being positive for SSEA-3(+) and negative for at least one member selected from the group consisting of (a) CD 117 and CD 146; (b) CD117, CD146, NG2, CD34, vWF, and CD271; (c) CD34, CD117, CD146, CD271, NG2; and vWF, Sox10, Snai1, Slug, Tyrp1, and Oct; and
 which:
 (a) exhibit telomerase activity no greater than that of human fibroblast; 
 (b) do not exhibit neoplastic growth; 
 (c) are capable of differentiating into three germ layers in vivo and in vitro ; and 
 (d) are capable of self-renewal. 
   
     
     
         5 . A cell fraction comprising at least 30% isolated SSEA-3(+) pluripotent cells (SSEA-3 (+) Muse cells) characterized by being positive for CD 105 and negative for at least member selected from the group consisting of (a) CD 117 and CD 146;
 (b) CD117, CD146, NG2, CD34, vWF, and CD271; (c) CD34, CD117, CD146, CD271, NG2, negative for vWF Sox10, Snai1, Slug, Tyrp1, and Oct;   which:
 (a) exhibit telomerase activity no greater than that of human fibroblast; 
 (b) do not exhibit neoplastic growth; 
 (c) are capable of differentiating into three germ layers in vivo and in vitro ; and 
 (d) are capable of self-renewal. 
   
     
     
         6 . The cell fraction of  claim 4  characterized by high phagocytic activity. 
     
     
         7 . The cell fraction of  claim 5  characterized by high phagocytic activity. 
     
     
         8 . The cell fraction of  claim 4  wherein at least the expression of the CD34 and CD117 cell markers is not observed. 
     
     
         9 . The cell fraction of  claim 5  wherein at least the expression of the CD34 and CD117 cell markers is not observed. 
     
     
         10 . The pluripotent cell fraction of  claim 8  comprising at least 50% of the SSEA-3 (+) Muse cells. 
     
     
         11 . The pluripotent cell fraction of  claim 8  comprising at least 70% of the SSEA-3 (+) Muse cells. 
     
     
         12 . The pluripotent cell fraction of  claim 8  comprising at least 90% of the SSEA-3 (+) Muse cells. 
     
     
         13 . The pluripotent cell fraction of  claim 8  comprising at least 95% of the Muse cells. 
     
     
         14 . The pluripotent cell fraction of  claim 9  comprising at least 50% of the isolated SSEA-3 (+) Muse cells. 
     
     
         15 . The pluripotent cell fraction of  claim 9  comprising at least 70% of the isolated SSEA-3 (+) Muse cells. 
     
     
         16 . The pluripotent cell fraction of  claim 9  comprising at least 90% of the isolated SSEA-3 (+) Muse cells. 
     
     
         17 . The pluripotent cell fraction of  claim 9  comprising at least 95% of the SSEA-3 (+) Muse cells. 
     
     
         18 . The pluripotent cell fraction of  claim 13  which is positive for Nanog, Oct3/4, SSEA-3, and Sox2. 
     
     
         19 . The pluripotent cell fraction of  claim 17  which is positive for Nanog, Oct3/4, SSEA-3, and Sox2. 
     
     
         20 . The pluripotent cell fraction of  claim 13  which is capable of systemic administration to treat damaged tissue or an organ. 
     
     
         21 . The pluripotent cell fraction of  claim 17  which is capable of systemic administration to treat damaged tissue or an organ.